Abstract

Multiple myeloma (MM) is characterized by multiple relapse and, despite the introduction of novel therapies, the disease becomes ultimately drug-resistant. The tumor microenvironment (TME) within the bone marrow niche includes dendritic cells, T-cytotoxic, T-helper, reactive B-lymphoid cells and macrophages, with a complex cross-talk between these cells and the MM tumor cells. Tumor-associated macrophages (TAM) have an important role in the MM pathogenesis, since they could promote plasma cells proliferation and angiogenesis, further supporting MM immune evasion and progression. TAM are polarized towards M1 (classically activated, antitumor activity) and M2 (alternatively activated, pro-tumor activity) subtypes. Many studies demonstrated a correlation between TAM, disease progression, drug-resistance and reduced survival in lymphoproliferative neoplasms, including MM. MM plasma cells in vitro could favor an M2 TAM polarization. Moreover, a possible correlation between the pro-tumor effect of M2 TAM and a reduced sensitivity to proteasome inhibitors and immunomodulatory drugs was hypothesized. Several clinical studies confirmed CD68/CD163 double-positive M2 TAM were associated with increased microvessel density, chemoresistance and reduced survival, independently of the MM stage. This review provided an overview of the biology and clinical relevance of TAM in MM, as well as a comprehensive evaluation of a potential TAM-targeted immunotherapy.

MeSH

Cells, Pharmaceutical Preparations, Plasma Cells, Macrophages, Neoplasms, Multiple Myeloma, Therapeutics, Tumor Microenvironment, Prognosis, Tumor-Associated Macrophages, Plasma, Drug Resistance

Cited by

• Computer-aided analysis reveals metallothionein-positive cancer-associated fibroblasts promote angiogenesis in gastric adenocarcinoma. Discov Oncol, 2024
• CD34 and CD34 MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34 MM cells. Int J Hematol, 2025
• Deciphering the bone marrow microenvironment's role in multiple myeloma immunotherapy resistance. Front Immunol, 2025
• Lipid metabolism in multiple myeloma: pathogenesis, therapeutic opportunities, and future directions. Front Oncol, 2025
• Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma. Biomolecules, 2023
• Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications. Cancers (Basel), 2024
• Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease. J Hematol Oncol, 2025
• Maraviroc enhances Bortezomib sensitivity in multiple myeloma by inhibiting M2 macrophage polarization via PI3K/AKT/RhoA signaling pathway in macrophages. Cell Div, 2025
• An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma. Clin Exp Med, 2024